T3D Therapeutics, Inc.
Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases.
Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases.
T3D Therapeutics, Inc. is a biotechnology startup founded in 2013, based in the United States. The company is dedicated to developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases. Their lead drug product candidate, T3D-959, is positioned as a potential ‘First-in-Class’ and ‘Best-in-Class’ breakthrough medicine for the treatment of Alzheimer’s disease. T3D Therapeutics aims to slow, stop, or even reverse the course of the disease. They have also initiated pre-clinical studies in Huntington’s Disease models, demonstrating the company's commitment to maximizing the therapeutic utility of T3D-959. The company recently received a significant $6.00MVenture Round investment on 03 September 2022. Though the specific investors for this round are not disclosed, this investment underscores the confidence in T3D Therapeutics' innovative approach and potential impact in addressing neurodegenerative diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.00M | - | 03 Sep 2022 | |
| Series B | $15.00M | 1 | National Institute on Aging | 04 Nov 2019 |
| Grant | $9.00M | - | 21 May 2019 | |
| Venture Round | $6.00M | - | 10 Mar 2018 | |
| Seed Round | $1.21M | - | 11 Mar 2016 |
No recent news or press coverage available for T3D Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
